A Study to Evaluate Infants With Potential Exposure to Tanezumab Before Birth
A Study to Evaluate Infants With Potential Exposure to Tanezumab Before Birth
This study will examine post-natal neurologic and cognitive development of infants who may
 have been exposed to tanezumab or comparator in-utero during the tanezumab clinical program
 (whether the exposure is through maternal or paternal participation in a tanezumab clinical
 study).
This study will enroll infants with potential tanezumab exposure in utero at sites overseen
 by Schulman and Associates IRB This study will attempt to enroll all infants who qualify.
Inclusion Criteria:

 Subject is an infant born to a mother who was exposed to study drug on a tanezumab clinical
 study through direct maternal exposure; or is an infant born to a mother who is a partner
 of a male patient who was exposed to study drug in a tanezumab clinical study prior to or
 around the time of conception and/or is exposed during his partner's pregnancy.

 Exclusion Criteria:

 There are no exclusion criteria for this study